Stocks Endo Health Solutions Inc

  • New York Attorney General Eric Schneiderman announced the settlement on Wednesday. Qualitest's misleading labels caused healthcare professionals to submit false reimbursement claims to Medicaid and federal health care plans, who then paid for vitamins that did not contain the fluoride amount stated on the label, the New York attorney general said.

  • Endo Health to pay $39 mln over fluoride labeling claims Wednesday, 16 Dec 2015 | 4:37 PM ET

    Dec 16- A generic drug maker owned by Endo International Plc has reached a $39 million settlement with the U.S. government and 47 states stemming from the unlawful labeling of multivitamins that contained fluoride. New York Attorney General Eric Schneiderman announced the settlement on Wednesday. The case stemmed from a 2013 whistleblower lawsuit filed...

  • Nov 12- Generic drug maker Mylan NV's $26 billion hostile bid for peer Perrigo Company Plc looked unlikely to succeed late on Thursday, a few hours before it was set to expire, according to people familiar with the matter. If confirmed, the outcome would represent a major victory for Perrigo's defiant Chief Executive Joseph Papa, and a bitter blow to Mylan's...

  • Oct 26- BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker's shares up 19 percent in premarket trading on Monday. Endo International Plc licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012..

  • BioDelivery's opioid treatment wins FDA approval Monday, 26 Oct 2015 | 6:15 AM ET

    Oct 26- The U.S. Food and Drug Administration has approved BioDelivery Sciences International Inc's opioid treatment for chronic pain, the company said on Monday. Endo International Plc licensed the worldwide manufacturing and marketing rights to the treatment, Belbuca, from BioDelivery in 2012.. Belbuca is an opioid film patch and aims to treat patients...

  • The firm's woes mean a likely loss of lucrative business for JPMorgan Chase& Co, Goldman Sachs Group Inc and other major investment banks. Since 2012, only General Electric Co, Allergan Plc, AT&T Inc and Dell Inc have paid more than Valeant in fees to Wall Street, according to data from Freeman and Co, a consulting firm. JPMorgan and Goldman Sachs have been top...

  • TORONTO/ NEW YORK, Oct 22- Valeant Pharmaceuticals International Inc moved to reassure investors on Thursday after being accused of using specialty pharmacies to inflate revenue, and said it would refute them in detail on a conference call with investors. Valeant said at least 10 of its executives and board members would participate in a call on Monday,...

  • NEW YORK, Oct 21- A simple promise turned Valeant Pharmaceutical International Inc and some of its rivals into stock market darlings: we will buy more companies and make more money selling drugs. Valeant's shares dropped as much as 39 percent on Wednesday, equivalent to about $20 billion, after Citron Research, a short-selling firm, published a report accusing it...

  • LOS ANGELES, Oct 21- Investor concerns over accounting practices at Valeant Pharmaceuticals International Inc have put a spotlight on the little-known and fast-growing specialty pharmacy industry. Shares of Valeant fell 19 percent on Wednesday after influential short-seller Citron Research accused the company of using specialty pharmacies, through a...

  • US STOCKS-Wall St declines; Valeant, healthcare weigh Wednesday, 21 Oct 2015 | 6:33 PM ET

    Oct 21- U.S. stocks fell on Wednesday as a sharp drop in Valeant Pharmaceuticals hit the healthcare space, while the energy sector dropped along with oil prices. Valeant Pharmaceuticals' U.S.-listed shares plunged to an intraday low of $88.50 on record volume after a short-seller accused the company of using specialty pharmacies to inflate its revenue.

  • US STOCKS-S&P 500, Nasdaq dip with healthcare, Yahoo Wednesday, 21 Oct 2015 | 3:39 PM ET

    *Valeant sinks after Citron report, drags Allergan, Endo. Oct 21- The S&P 500 and Nasdaq slipped in choppy trading late Wednesday afternoon as insurers and other big healthcare names dropped and Yahoo shares fell following disappointing results. Shares of Allergan, which has a business model similar to that of Valeant, fell 4.6 percent to $251.37, though the...

  • Valeant bonds plunge on short-seller report Wednesday, 21 Oct 2015 | 2:49 PM ET

    NEW YORK, Oct 21- Valeant bonds dropped as much as 12 points on Wednesday after an explosive report from a short-seller accused the company of fraudulently inflating its revenue numbers. Valeant blasted the "erroneous" report but investors were already racing for the exits, sending its 7.5% 2021 s down 12 points to a cash price of 90.5, according to MarketAxess.

  • NEW YORK, Oct 21- Valeant Pharmaceuticals International Inc plunged as much as 40 percent after an influential short-seller accused the company of using specialty pharmacies to inflate its revenue, an allegation that the drugmaker denied. Citron Research, a short-selling firm run by Andrew Left, alleged that Valeant's previously undisclosed ties to...

  • *Valeant sinks after Citron report, drags Allergan, Endo. Oct 21- Wall Street was little changed in early afternoon trading on Wednesday as gains by General Motors and technology stocks were limited by a slide in healthcare stocks. Allergan fell 4.6 percent to $251.37 and Endo International slumped nearly 13 percent to $54.98, weighing the most on the S&P 500 and...

  • NEW YORK, Oct 21- Shares of Valeant Pharmaceuticals International Inc plunged as much as 30 percent after an influential short-seller accused the company of fraud, saying it used its relationship with specialty pharmacies to inflate revenue. The Citron Research report hit shares hard shortly after 10 a.m. EDT in New York trading. Shares of some key competitors,...

  • Sept 9- The U.S. Food and Drug Administration's staff expressed concerns over the risk of incorrectly administering Colleguim Pharmaceuticals Inc's long-acting opioid painkiller. Reviewers said if the FDA eventually determines that Xtampza's benefits outweigh its risks, the company should assess the effectiveness of its packaging in preventing...

  • Chicago sues drugmakers, alleging painkiller risk Tuesday, 3 Jun 2014 | 10:37 AM ET

    Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.

  • Early movers: AOL, KORS, TMUS, CVS, AIG & more Tuesday, 5 Nov 2013 | 7:38 AM ET

    Some of the names on the move ahead of the open.

  • market-insider-stocks-to-watch-AB-200.jpg

    Check out which companies are making headlines after the bell Wednesday:

  • After-Hours Buzz: GPS, CRM, GRPN & More Thursday, 28 Feb 2013 | 3:40 PM ET
    market-insider-stocks-to-watch-AB-200.jpg

    Check out which companies are making headlines after the bell Thursday: